Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative…
News
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative…
Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client
VKVP Haulage adopts Fingerprint Drug Screening System to help drive proactive drug testing policy Auctus…
Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client
VKVP Haulage adopts Fingerprint Drug Screening System to help drive proactive drug testing policy Auctus…
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX)…
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX)…
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party…
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party…
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be…
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be…
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the…
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the…
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ)…
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ)…
Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or…
Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or…